FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. by Norrmén, C. et al.
JCB: ARTICLE
The Rockefeller University Press  $30.00
J. Cell Biol. Vol. 185 No. 3 439–457
www.jcb.org/cgi/doi/10.1083/jcb.200901104 JCB 439
Correspondence to Tatiana V. Petrova: tatiana.petrova@unil.ch
K.I. Ivanov and J. Cheng’s present address is Division of Experimental 
Oncology, Multidisciplinary Oncology Center, University of Lausanne, 1066 
Epalinges, Switzerland.
V. Horsley’s present address is Dept. of Molecular, Cellular, and Developmental 
Biology, Yale University, New Haven, CT 06520.
Abbreviations used in this paper: CEAS, cis-regulatory element annotation sys-
tem; ChIP, chromatin immunoprecipitation; CsA, cyclosporine A; EMSA, electro-
phoretic mobility shift assay; FDR, false discovery rate; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; iLEC, intestinal LEC; LEC, lymphatic endothelial 
cell; MAT, model-based analysis of tiling array; NFAT, nuclear factor of activated 
T cells; SLC, secondary lymphoid chemokine; SMA, smooth muscle actin; SMC, 
smooth muscle cell.
Introduction
The formation of lymphatic vessels, whose main function is to 
drain interstitial fluid from the tissues back to the blood circula-
tion, begins only after the blood circulation is already func-
tional. The initial steps of lymphatic development are controlled 
by the transcription factors Sox18 and Prox1 and VEGF-C and 
its receptor VEGFR-3 (Kukk et al., 1996; Dumont et al., 1998; 
Wigle and Oliver, 1999; Karkkainen et al., 2004; Francois et al., 
2008). Expression of Prox1 is induced by Sox18 in a restricted 
subset of endothelial cells in the embryonic jugular veins (Wigle 
and Oliver, 1999; Francois et al., 2008). These VEGF-C– 
responsive cells sprout and migrate to form the primary lymphatic 
sacs, which further remodel to form a primary lymphatic capil-
lary plexus (van der Putte, 1975; Karkkainen et al., 2004). The 
primary plexus undergoes further morphological and molecular 
changes to form a mature lymphatic network composed of 
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maturation of the primary lymphatic capillary plexus 
into collecting lymphatic vessels during development 
and show that forkhead transcription factor Foxc2 con-
trols this process. We further identify transcription factor 
NFATc1 as a novel regulator of lymphatic development 
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NFATc1 and Foxc2 in the regulation of lymphatic matu-
ration. We also provide a genome-wide map of FOXC2-
binding sites in lymphatic endothelial cells, identify a 
novel consensus FOXC2 sequence, and show that 
NFATc1 physically interacts with FOXC2-binding en-
hancers. As damage to collecting vessels is a major 
cause of lymphatic dysfunction in humans, our results 
suggest that FOXC2 and NFATc1 are potential targets 
for therapeutic intervention.
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Prox1, and LYVE-1 in mouse mesenteric lymphatic vessels 
during development. The mesenteric lymphatic primordia can 
first be identified at embryonic day (E) 13.5 near the splenic and 
superior mesenteric veins (van der Putte, 1975). At E14.5, stain-
ing for lymphatic endothelial receptor tyrosine kinase VEGFR-3 
showed numerous isolated clusters or single lymphatic endothe-
lial cells (LECs) extending long filopodia (Fig. 1 A and Fig. S1 A). 
These cell clusters, located on both sides along the mesenteric 
blood vessels, migrate and sprout toward each other along 
and across the blood vessels. By E15.5, LECs form a mesh-like 
network of highly branched capillary-like vessels surrounding 
the mesenteric arteries and veins (Fig. 1 B). After E15.5, the 
mesenteric lymphatic capillary plexus undergoes substantial 
morphological changes, leading to formation of collecting lym-
phatic vessel trunks by E17.5, characterized by even diameter, 
presence of intraluminal valves, and absent or little branching 
(Fig. 1, C and D). These features become even more pronounced 
in the postnatal collecting vessels (Fig. 1 E).
On the molecular level, E14.5–15.5 lymphatic vessels 
express uniformly high levels of Prox1 and VEGFR-3 (Fig. 1, 
A and K). At E14.5, LYVE-1 expression was absent in lymphatic 
vessels in the skin, whereas the lymph sacs show high LYVE-1 
expression (Fig. S1, B–E). Interestingly, in the mesenterium, 
only a small subset of LECs express LYVE-1 at this time point 
(Fig. S1, G and L). At E14.5, Foxc2 is mainly expressed in 
arterial smooth muscle cells (SMCs), and Foxc2 levels are high 
only in a few isolated LECs (Fig. 1 F). Strikingly, by E15.5, all 
LECs express high levels of Foxc2 (Fig. 1 G). Up-regulation of 
Foxc2 expression is followed by an increase in LYVE-1 levels, 
which becomes present in all LECs by E16.5 (Fig. S1, H–N). 
Between E15.5 and 16.5, the expression of first Foxc2 and then 
Prox1 begins to decrease except in the areas of characteristic 
constrictions, which delineate forming lymphatic valves, and by 
E17.5, only weak expression can be detected in the lymphan-
gion segments between the valves (Fig. 1, G–J, L–O, and Q–T). 
Foxc2 and Prox1 down-regulation is followed by a decrease of 
VEGFR-3 and LYVE-1 at E17.5–postnatal day (P) 9, but 
VEGFR-3 remains high in the valve leaflets, whereas LYVE-1 
expression becomes very low in all collecting LECs, as it has 
been reported previously (Fig. 1, D and E; and Fig. S1, J, K, O, 
and P; Makinen et al., 2005). In the fully mature postnatal col-
lecting lymphatic vessels, the expression of Foxc2, Prox1, and 
VEGFR-3 in vessel trunks is even weaker, whereas the expres-
sion in the valves remains high.
The presence of a thin basement membrane and a sparse 
coating with mural cells is another characteristic feature of col-
lecting lymphatic vessels. We found that accumulation of base-
ment membrane protein collagen IV starts at E16.5 (Fig. 2, 
A–J). NG2-positive mural cells start to appear around the form-
ing collecting vessels at E17.5, whereas  smooth muscle actin 
(SMA)–positive SMCs are prominent only after birth (Fig. 2, 
A–E and K–X).
In summary, the formation of lymphatic collecting vessels 
starts at E14.5–15.5, which is coincident with up-regulation of 
Foxc2 (Fig. 1 U). This is followed by remodeling of the primary 
capillary plexus and formation of a single lymphatic trunk, at 
which point the expression of Foxc2 decreases except in the areas 
lymphatic capillaries responsible for the uptake of lymph from 
the interstitial space and collecting lymphatic vessels that trans-
port the lymph back to the blood circulation. Mature collecting 
vessels are characterized by a thin basement membrane, sparse 
pericyte coverage, and have intraluminal valves to prevent back-
flow of the fluid. Lymphatic capillaries, however, lack valves 
and a pericyte layer. These later steps of lymphatic vascular 
development, the maturation of the primary lymphatic plexus into 
functional collecting vessels and capillaries, are at present not 
well understood.
Loss of forkhead transcription factor Foxc2 leads to de-
fects in lymphatic remodeling, failure to form lymphatic valves, 
and increased pericyte coverage of lymphatic vessels (Petrova 
et al., 2004). In lymphedema-distichiasis (Online Mendelian 
Inheritance in Man reference no. 153400), a disease caused by 
mutations in FOXC2, the patients have a similar phenotype to 
Foxc2/ mice with abnormal lymphatic vessel pericyte coverage 
(Petrova et al., 2004). Lymphedema-distichiasis patients also 
show reflux of tracer in a lymphoscintigram, indicating failure 
or absence of valves in their collecting lymphatic vessels (Brice 
et al., 2002). Interestingly, a recent study shows linkage of FOXC2 
mutations to varicose veins and primary valve failure in veins, 
suggesting that FOXC2 controls the formation of venous valves 
(Mellor et al., 2007).
The transcription factor NFATc1 belongs to a family of 
calcium-sensitive transcription factors activated by calcineurin-
dependent dephosphorylation (for review see Crabtree and 
Olson, 2002). Activation of nuclear factor of activated T cells 
(NFAT) proteins results in exposure of a nuclear localization 
sequence and subsequent translocation to the nucleus. Once in 
the nucleus, NFATc1 interacts with other transcription factors, 
including AP-1, nuclear factor B, Foxp3, and GATA, to form 
regulatory complexes on DNA (Kinoshita et al., 1997; Musaro 
et al., 1999; Macian et al., 2001; Wada et al., 2002; Sakuma et al., 
2003; Bettelli et al., 2005). NFATc1 is implicated in the regula-
tion of immune cells as well as in osteogenesis and hair follicle 
stem cells (Macian, 2005; Takayanagi, 2007; Horsley et al., 
2008). Studies of NFATc1-deficient mice have also revealed an 
essential role for NFATc1 in the morphogenesis of cardiac valves 
(de la Pompa et al., 1998; Ranger et al., 1998).
In this study, we have characterized the steps of lymphatic 
vascular maturation, which lead to the formation of two morpho-
logically and molecularly distinct parts of the lymphatic vascu-
lar system: collecting lymphatic vessels and capillaries. We show 
that Foxc2 controls this process, and in the absence of Foxc2, 
lymphatic vessels fail to undergo transformation toward a lym-
phatic collecting vessel phenotype. Furthermore, we demonstrate 
that NFATc1 is a novel regulator of lymphatic vascular matura-
tion and that it cooperates with Foxc2 in this process.
Results
Molecular characterization of developing 
collecting lymphatic vessels
To characterize the process of collecting lymphatic vessel for-
mation, we studied morphological changes and the expression 
of the lymphatic endothelial-specific markers VEGFR-3, Foxc2, 
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Figure 1. Expression of lymphatic endothelial markers 
during formation of collecting lymphatic vessels. (A–T) 
Whole-mount immunofluorescent staining of wild-type mes-
enteric vessels at the indicated ages for VEGFR-3 (A–E), 
Foxc2 (F–J and P–T), and Prox1 (K–O and P–T). At E14.5, 
Foxc2 is expressed in a few LECs (arrow), whereas arte-
rial SMCs are Foxc2 positive (arrowhead). (U) Schematic 
summary of the expression of lymphatic markers during 
lymphatic collecting vessel maturation. Bars, 100 µm.
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network, suggested that Foxc2 controls lymphatic vascular matu-
ration. Indeed, in Foxc2/ mice, lymphatic vessels fail to down-
regulate Prox1, VEGFR-3, and LYVE-1 (Fig. 3). In contrast, 
the collecting vessels in the mesentery of E17.5 heterozygous 
littermates show a normal expression pattern with low levels of 
VEGFR-3 and Prox1 in the lymphangion, high expression in 
the valves (Fig. 3, A and E), and uniformly low expression of 
LYVE-1 throughout the whole collecting vessel (Fig. 3 G). The 
lymphatic capillaries continue to express high levels of LYVE-1 
both in Foxc2/ mice and in heterozygous littermates (Fig. 3, 
G and H). The secondary lymphoid chemokine (SLC) is also 
highly expressed in the immature collecting vessels in Foxc2/ 
mice, whereas it is present only in the valves of the collect-
ing vessels of Foxc2+/+ mice (Fig. 3, I and J). In addition, the 
of the forming lymphatic valves, and is further followed by a 
decrease in Prox1, VEGFR-3, and LYVE-1 expression. Accumu-
lation of basement membrane proteins starts at E16.5 followed 
by recruitment of NG2-positive mural cells at E17.5 and SMCs 
postnatally. These data uncover a highly dynamic spatiotempo-
ral expression profile for LEC markers during the formation and 
maturation of collecting lymphatic vessels and suggest that the 
change in Foxc2 expression is the critical first event of the matu-
ration process.
Loss of Foxc2 prevents formation of 
collecting lymphatic vessels
Up-regulation of Foxc2 at E15.5, which precedes the mor-
phological and molecular changes in the maturing lymphatic 
Figure 2. Formation of basement membrane and mural cell coating during maturation of lymphatic collecting vessels. (A–X) Whole-mount immunofluor-
escent staining of wild-type mesenteric vessels at the indicated ages for VEGFR-3 (A–E), collagen IV (F–J), SMA (K–O), and NG2 (P–X). Accumulation 
of basement membrane to collecting lymphatic vessels occurs at E16.5 (C and H, arrows), whereas recruitment of SMCs occurs between E17.5 and P9 
(E and O, arrows), and NG2-positive mural cells appear around the vessels at E17.5 (R and V, arrows). Bars, 100 µm.
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We observed uniform membranous staining for VEGFR-3 in wild-
type collecting vessels, which is consistent with a quiescent 
VEGF-C–VEGFR-3 pathway (Fig. 3 C). In contrast, VEGFR-3 in 
Foxc2/ mice was concentrated in grainy dots and largely absent 
from the cell surface, which is similar to sprouting lymphatic capil-
laries (Fig. 3 D and Fig. S1 F). Although the exact reason for the 
increased VEGFR-3 internalization remains to be investigated, it 
collecting vessels in Foxc2/ mice are more highly branched, 
which may reflect incomplete intussusceptive vascular pruning 
(Burri et al., 2004).
Activation of VEGFR-3 after binding to its ligand VEGF-C 
is followed by internalization of the receptor observed in cultured 
LECs and in sprouting lymphatic capillaries in vivo (Makinen 
et al., 2001; Veikkola et al., 2001; Wirzenius et al., 2007). 
Figure 3. Foxc2 is essential for the formation 
of collecting lymphatic vessels. (A–J) Mesen-
teric lymphatic vessels fail to down-regulate 
VEGFR-3, Prox1, and SLC in the absence of 
Foxc2. Whole-mount immunofluorescent staining 
for VEGFR-3 (A–D), Prox1 (E and F), LYVE-1 
(G and H), and SLC (I and J) in E17.5 Foxc2/ 
or control embryos. (C and D) Internalization 
of VEGFR-3 in lymphatic vessels of Foxc2/ 
mice but not control E17.5 embryos. (K and L) 
Increased Angpt2 expression in lymphatic 
vessels of Foxc2/ mice. In situ hybridization 
for Angpt2 (blue) and immunohistochemical 
staining for VEGFR-3 (red). Arrows, lymphatic 
valves (A, E, and I) or collecting lymphatic vessels 
(G and H); arrowheads, lymphatic capillaries; 
dashed lines, lymphatic vessels. Bars: (A, B, 
and E–J) 100 µm; (C, D, K, and L) 25 µm.
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is indicative of active VEGFR-3 signaling and further confirms 
the failure of Foxc2/ lymphatic vessels to adopt a collecting 
vessel phenotype. Angiopoietin-2 (Ang2 and Angpt2), a ligand 
of Tie2 endothelial receptor tyrosine kinase, is important in the 
regulation of blood vascular maturation and stabilization but is 
also essential for normal lymphatic development. Angpt2-defi-
cient mice display disorganized and hypoplastic lymphatic capil-
laries and an aberrant recruitment of periendothelial cells to 
lymphatic capillaries (Gale et al., 2002; Shimoda et al., 2007; 
Dellinger et al., 2008). Ang2 is produced by LECs in vivo 
(Fig. S2 F; Dellinger et al., 2008), and its expression is induced in 
cultured LECs upon treatment with VEGF-C (Veikkola et al., 
2003). In agreement with the increased VEGFR-3 internalization, 
we observed higher levels of Angpt2 in Foxc2-deficient lymphatic 
endothelia (Fig. 3, K and L). Activation of VEGFR-3 also leads 
to enhanced sprouting of lymphatic capillaries, accompanied by 
formation of filopodia (Saaristo et al., 2002a; Wirzenius et al., 
2007). We observed abundant lymphatic sprouting in the devel-
oping lymphatic vasculature in the skin of wild-type mice (Fig. 4, 
A–E). In contrast, Foxc2/ lymphatic vessels contained 
numerous blunt-ended protrusions devoid of filopodia, which 
were closely associated with a surrounding layer of basement 
membrane protein collagen IV (Fig. 4, F–J).
Collectively, our data show that loss of Foxc2 leads to a 
failure in the maturation of the primary lymphatic plexus into 
functional collecting lymphatic vessels and capillaries. Instead, 
the Foxc2/ lymphatic vasculature is characterized by a persis-
tent expression of the lymphatic capillary markers Prox1, 
VEGFR-3, LYVE-1, and SLC, failure to down-regulate VEGFR-3 
signaling, and abnormal capillary sprouting.
NFATc1 is expressed in LECs and is 
controlled by PROX1 and VEGF-C
Failure to form intraluminal valves is a characteristic feature of 
Foxc2/ lymphatic vessels (Petrova et al., 2004), which led us 
to investigate the potential for cooperation between Foxc2 and 
pathways implicated in the regulation of heart valve develop-
ment such as Wnt and NFAT (Armstrong and Bischoff, 2004). 
We did not observe -galactosidase expression in the lymphatic 
valves of the Wnt reporter mice TOP-Gal or BAT-Gal, whereas 
strong LacZ staining was observed in cardiac valves as reported 
previously (DasGupta and Fuchs, 1999; Maretto et al., 2003; 
unpublished data). Similarly, reporter expression was not modi-
fied in the absence of Foxc2 in TOP-Gal;Foxc2/ or BAT-
Gal;Foxc2/ mice (unpublished data).
However, for NFATc1, we detected previously unsus-
pected expression and activity in the lymphatic vasculature. 
At E12.5, nuclear NFATc1 was present in LECs of the lymph sacs. 
At E13.5, NFATc1 was mainly detected in the cytoplasm and, at 
lower levels, in the nuclei of endothelial cells of the lymph sacs. 
Mostly nuclear localization was observed from E14.5 onwards 
(Fig. 5, A–H). Notably, no significant expression of NFATc1 
was detected in blood vessels at E12.5–17.5 nor in other Prox1-
expressing tissues, such as the spinal cord (Fig. S2, B and C; 
unpublished data), suggesting a LEC-specific function in addi-
tion to the previously described role in endocardial cells (de 
la Pompa et al., 1998; Ranger et al., 1998; Chang et al., 2004). 
Figure 4. Defective sprouting of lymphatic vessels in Foxc2/ mice. (A–J) 
Whole-mount immunofluorescent staining for VEGFR-3 (green), LYVE-1 
(red), and collagen IV (white) of skin from E17.5 wild-type and Foxc2/ 
embryos. Note the close association of collagen IV and aborted sprouts 
in Foxc2/ lymphatic vessels (I and J), whereas no collagen is deposited 
around wild-type lymphatic vessels (D and E). Bars: (A and F) 100 µm; 
(B–E and G–J) 50 µm.
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Figure 5. Expression and regulation of NFATc1 in LECs. (A–H) Immunofluorescent staining for NFATc1 (green), Prox1 (red), and DNA (blue) at E12.5–17.5. 
Arrowheads, cytoplasmic staining. (I) Western blotting for the indicated proteins of iLECs transfected with PROX1 siRNA, control siRNA, or iLECs and 
control cell line SW480A (a subclone of colon carcinoma cell line) transduced with AdPROX1 or control AdLacZ. (J and K) NFATc1 activation is VEGF-C 
and VEGFR-2 dependent. Cells were stimulated with the indicated growth factors or BSA in the presence and absence of CsA and stained for NFATc1 
(red) and PROX1 (green). (J) Quantification of nuclear intensity of NFATc1 in iLECs. Data are presented as mean percentual nuclear intensity ± SEM. 
**, P < 0.001. RU, relative intensity unit. Bars, 20 µm.
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before the formation of fully mature collecting lymphatic ves-
sels (de la Pompa et al., 1998; Ranger et al., 1998), we treated 
mice with cyclosporine A (CsA), an inhibitor of calcineurin 
activity, and thus dephosphorylation and nuclear translocation of 
NFAT transcription factors (Graef et al., 2001). CsA treatment 
at E11 reproduces the cardiac valve defects seen in Nfatc1/ 
mice, whereas CsA administration at E12 does not affect the 
heart valves or the viability of the embryos (Chang et al., 2004). 
To avoid interference with heart development, we treated wild-
type and Foxc2+/ pregnant females at E12.5–16.5 and analyzed 
the vasculature at E17.5. As expected (Chang et al., 2004), CsA 
reduced the nuclear localization of NFATc1 in LECs (Fig. S2, 
K–N), but it did not affect the viability and overall appearance 
of the embryos (Fig. 6 C). Similarly, the blood vasculature of 
CsA-treated embryos did not differ from that of the control mice 
and displayed normal formation of veins, arteries, and capillary 
bed, appropriate coverage with SMCs, and normal blood vascu-
lar density (Fig. 6, D–K; unpublished data).
In contrast, CsA treatment resulted in abnormal lymphatic 
vessel patterning, lymphatic vessel hyperplasia, defective re-
modeling of mesenteric collecting vessels, and recruitment of 
SMCs to dermal lymphatic capillaries (Fig. 7, A–P and Q; and 
Fig. 8, A–H), which are phenotypes consistent with the early 
remodeling defects observed in Nfatc1/ mice and reminiscent 
of the phenotype of Foxc2/ mice. These defects were espe-
cially pronounced in the lymphatic vessels of CsA-treated 
Foxc2+/ embryos (Fig. 7, K–P). Furthermore, the lymphatic 
vessels of CsA-treated mice failed to down-regulate VEGFR-3, 
Prox1 (Fig. 7, A–P), and LYVE-1 (unpublished data), and CsA-
treated Foxc2+/ mice completely lacked lymphatic valves, 
whereas CsA-treated wild-type mice had a significantly reduced 
number of valves (Fig. 7, F, N, P, and R). Similar to lymphatic 
vessels in Foxc2/ mice, we also observed increased internal-
ization of VEGFR-3 (Fig. 8, I–L) and higher Angpt2 levels (Fig. 8, 
M and N). The blunt aborted sprouts seen in the lymphatic 
capillaries of Foxc2/ mice were also present in CsA-treated 
Foxc2+/ mice (Fig. 7 O). Injection of FITC-dextran into the 
hind limbs of E17.5 Foxc2+/ CsA-treated embryos demon-
strated abnormal outflow from the collecting lymphatic vessels 
to the precollector vessel branches, whereas only the collecting 
lymphatic vessel trunks were visualized in control embryos, 
further confirming loss of collecting vessel function (Fig. 7, 
S and T). Foxc2 was present in all LECs of CsA-treated mice, 
demonstrating that NFAT signaling does not control Foxc2 
expression or protein stability (Fig. S2, O and P), thus, the lym-
phatic defects are not caused by the lack of Foxc2. Conversely, 
Foxc2/ mice showed normal NFATc1 expression (unpub-
lished data).
Collectively, these data show that suppression of NFATc1 
activation during the late stages of embryogenesis prevents the 
formation and maturation of collecting lymphatic vessels with-
out affecting blood vascular development in a manner highly 
reminiscent of the Foxc2 knockout phenotype. Moreover, loss 
of one Foxc2 allele strongly potentiates the effects of NFAT 
pathway inhibition. Together with the colocalization of Foxc2 
and NFATc1 in developing collecting vessels, this suggests a 
functional cooperation between these two signaling cascades.
The in situ hybridization analysis demonstrated expression of 
NFATc1 in lymphatic vessels, especially in the valves, further con-
firming our observations (Fig. S2, D–F). A more detailed analysis 
of Foxc2 and NFATc1 expression revealed that these transcription 
factors are present only in a subset of LECs and are largely co-
expressed as determined by double staining (Fig. S2 G). More-
over, in embryonic and adult skin, Foxc2 expression is mainly 
detected in lymphatic collecting vessels, but not in capillaries, 
further confirming that Foxc2 is a regulator of collecting vessel 
identity (Fig. S2, H–J; unpublished data).
Because of the specific expression of NFATc1 in lymphatic 
but not blood vascular endothelial cells, we investigated the po-
tential regulation of NFATc1 expression by PROX1, which con-
trols LEC commitment (Petrova et al., 2002; Wigle et al., 2002). 
Indeed, overexpression of PROX1, using adenoviral gene transfer 
in primary human intestinal LECs (iLECs), increased NFATc1 
levels, whereas PROX1 overexpression in nonendothelial cells 
did not have any effect on NFATc1 expression (Fig. 5 I). Consis-
tently, siRNA-mediated knockdown of PROX1 resulted in de-
creased NFATc1 levels (Fig. 5 I).
VEGF stimulates nuclear translocation of NFATc1 and in-
creases proliferation in human pulmonary valve endothelial cells 
(Johnson et al., 2003). This led us to investigate whether VEGF-C, 
which has been shown to promote the formation of collecting 
vessels in addition to its role in lymphatic endothelial prolifera-
tion and sprouting (Tammela et al., 2007), can activate NFATc1 
in LECs. Indeed, treatment of iLECs with VEGF-C resulted in 
strong accumulation of nuclear NFATc1, whereas control BSA-
treated cells showed only little nuclear NFATc1 staining (Fig. 5, 
J and K). VEGF-E, a viral homologue of VEGF that signals through 
VEGFR-2 (Ogawa et al., 1998; Meyer et al., 1999), also increased 
nuclear NFATc1, whereas VEGF-C156S, a mutant form of VEGF-C 
that unlike wild-type VEGF-C does not bind to VEGFR-2 but 
only to VEGFR-3 (Joukov et al., 1998), did not have a marked ef-
fect on nuclear accumulation of NFATc1 in spite of the activation 
of ERK1/2 phosphorylation (Fig. 5, J and K; and Fig. S3 A). In con-
trast to its effect on nuclear translocation of NFATc1, VEGF-C 
treatment did not increase NFATc1 mRNA levels (Fig. S3 B), and 
conversely, overexpression of PROX1 in LECs did not lead to a 
specifically nuclear increase in NFATc1 but rather to increased 
overall protein levels (Fig. S3 C). Collectively, our data indicate 
that NFATc1 is expressed in a subset of LECs and that its levels 
are controlled by PROX1, whereas its activity and nuclear trans-
location are regulated by VEGF-C through activation of VEGFR-2 
or VEGFR-2–VEGFR-3 heterodimers.
Inhibition of NFAT signaling prevents 
formation of collecting lymphatic vessels
Next, we studied whether inhibition of NFATc1 signaling af-
fects lymphatic vascular development in vivo. The initial LEC 
commitment was not affected in mice deficient in Nfatc1, as 
determined by staining for Prox1 (unpublished data). However, 
lymphatic capillaries in mice surviving until E15.5 were abnor-
mally patterned, tortuous, and widened, which is reminiscent of 
the lymphatic vessels in Foxc2/ mice (Fig. 6, A and B). These 
data suggested that NFATc1 controls the remodeling steps of 
lymphatic vascular development. Because Nfatc1/ mice die 
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ing led us to investigate a possible link between FOXC2 and 
NFATc1. FOXC2 and NFATc1 coimmunoprecipitated, indicat-
ing that the two transcription factors physically interact at least 
when overexpressed (Fig. S3 D). To gain a mechanistic 
ChIP-chip analysis of FOXC2-binding sites 
reveals cooperation with NFAT signaling
The similarities between the lymphatic maturation defects in 
Foxc2-deficient mice and mice with inhibited NFATc1 signal-
Figure 6. Defective lymphatic and normal blood vessel development upon loss of NFAT signaling. (A and B) Abnormal lymphatic vessel patterning in 
NFATc1/ embryos. Whole-mount immunofluorescent staining of E15.5 skin for LYVE-1. Bars, 200 µm. (C) Normal macroscopic appearance of E17.5 
embryos after administration of CsA. (D–K) Normal blood vessel morphology and SMC coverage after administration of CsA. Whole-mount immunofluor-
escent staining for PECAM-1 (green) and SMA (red) of control and CsA-treated skin and mesenteric vessels of E17.5 wild-type, Foxc2+/, and Foxc2/ 
embryos. Mesent, mesentery. Bars: (skin) 200 µm; (mesentery) 100 µm.
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Figure 7. NFAT signaling is necessary for the formation of collecting lymphatic vessels. (A–P) NFAT inhibition prevents maturation of lymphatic vessels. 
Whole-mount immunofluorescent staining for VEGFR-3 (green) and Prox1 (red) of mesenteries and skins of control (A–H) or CsA-treated (I–P) E17.5 
embryos. Arrows, lymphatic valves. (Q) Quantification of mean lymphatic vessel width from control and CsA-treated E17.5 dermal lymphatic capillaries 
(n = 4). (R) Quantification of mesenteric lymphatic valves. n = 4 per genotype. *, P < 0.005; **, P < 0.001. (S and T) Lymph backflow in CsA-treated 
embryos. Collecting lymphatic vessels were visualized after high molecular weight FITC-dextran injection into E17.5 embryos. Data are presented as mean ± 
SEM. Bars: (A–D and J–L) 100 µm; (E–H and M–P) 200 µm; (S and T) 500 µm.
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understanding of the FOXC2-mediated transcriptional network, 
we performed genome-wide location analysis of endogenous 
FOXC2 in primary LECs. We used chromatin immunoprecipi-
tation (ChIP) coupled with tiling microarrays covering the 
entire human genome (ChIP-chip) to produce an unbiased high 
resolution map of FOXC2-binding sites. For each ChIP-chip 
biological replicate, the immunoprecipitation was verified 
by Western blotting with anti-FOXC2 antibody (Fig. S4 A). 
Figure 8. Inhibition of NFAT signaling in vivo prevents maturation of collecting lymphatic vessels. (A–H) Ectopic SMCs in lymphatic capillaries of Foxc2/ 
and CsA-treated embryos. Whole-mount immunofluorescent staining for SMA (red) and Prox1 (green) of embryonic skin at E17.5. Arrows, SMA-positive 
lymphatic vessels. (I–L) Increased VEGFR-3 internalization in lymphatic vessels of CsA-treated Foxc2+/ embryos. Whole-mount immunofluorescent staining 
for VEGFR-3 (green/gray) and Prox1 (red). (M and N) Increased expression of Angpt2 upon inhibition of NFAT signaling. In situ hybridization for Angpt2 
(blue) and immunohistochemical staining for VEGFR-3 (red) at E17.5. Boxed areas indicate regions shown at higher magnifications in J and L. Bars: 
(A–L)100 µm; (M and N) 25 µm.
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Figure 9. Location analysis of FOXC2-binding sites in LECs. (A) Visualization of several FOXC2-binding regions. MAT score for each tiling array probe is 
shown in blue. Purple bars indicate FOXC2-enriched regions. Red peaks indicate ChIP regions selected for validation by EMSA. Potential target genes are 
indicated below the enrichment profile. Vertical lines, exons; horizontal lines, introns. Arrowheads indicate the direction of transcription. (B) Validation of 
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ChIP DNA was amplified using the whole genome amplification 
method, which introduces very little bias compared with a com-
monly used linker-mediated PCR procedure (O’Geen et al., 2006). 
A total of 2350 FOXC2-binding sites were identified in LECs at 
a false discovery rate (FDR) of 0.1% (Fig. 9 and supplemental 
data). Because low yields of ChIP DNA from primary LECs 
precluded large-scale validation of ChIP-chip results by quanti-
tative PCR, we used an alternative validation strategy by elec-
trophoretic mobility shift assay (EMSA). We PCR amplified 
200-bp fragments from nine randomly selected ChIP peak 
regions (Fig. S4 D) and tested them in EMSA with nuclear 
extracts from LECs transduced with FOXC2- (AdFOXC2) or 
control -galactosidase–expressing adenoviruses (AdLacZ). 
The selection of ChIP regions was unbiased with respect to 
model-based analysis of tiling array (MAT) score, p-value, 
FDR, or fold change. As expected, FOXC2 formed stable com-
plexes with all ChIP region fragments but not with the control 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) fragment, 
and no specific complexes were observed with control nuclear 
extracts from cells transduced with AdLacZ (Fig. 9 B). The 
FOXC2–DNA complexes could be supershifted with anti-FOXC2 
but not control antibodies (Fig. S4 B; unpublished data), and 
point mutations in the forkhead-binding motif totally abolished 
the probe interaction with FOXC2 (Fig. S4 C).
Analysis of ChIP-chip data revealed that >90% of FOXC2-
binding sites were located in distal intergenic regions and 
gene introns, and <1% of sites were located in the proximal 
promoter regions (Fig. 9 C). Notably, there was a high degree 
of conservation of FOXC2-binding sites among higher eukary-
otes (Fig. 9 D), suggesting that the FOXC2-regulated transcrip-
tional network in lymphatic vascular development is conserved 
across species.
De novo motif discovery analysis revealed a common se-
quence motif in ChIP regions, which strongly resembled that of 
Freac-3 (FOXC1) from the TRANSFAC database. Both the newly 
discovered motif and the Freac-3 motif contained the 3-terminal 
forkhead-binding element (T/A/C)AAACA preceded by an 
adenine-rich tract (Fig. 9 E). Such similarity between the two 
motifs is in good agreement with the fact that Freac-3/FOXC1 and 
FOXC2 have nearly identical DNA-binding domains (Saleem 
et al., 2004). The motifs, however, were completely different fur-
ther upstream, which likely reflects fundamentally different 
approaches used for their identification. The Freac-3 motif has 
been identified by in vitro PCR selection using GST-tagged DNA-
binding domain of FOXC1 (Pierrou et al., 1994), whereas the 
motif discovered in this study was derived from ChIP-chip exper-
iments performed with endogenous FOXC2 in primary cells.
We further studied whether the ChIP-chip data could sug-
gest an explanation for the observed physical interaction of 
FOXC2 and NFATc1 as well as for their functional cooperation 
in the in vivo models. We performed enrichment analysis of all 
human transcription factor–binding sites from the TRANSFAC 
database in the FOXC2 ChIP sequences. NFAT-binding sites 
were significantly enriched (M00302, 2.07 fold change and 95% 
confidence interval [1.96; 2.19]; M00935, 1.95 fold change [1.84; 
2.07]), whereas no statistically significant enrichment was seen 
for any of the control transcription factors (Fig. 10 A). Similarly, 
no enrichment was observed for transcription factors specifically 
expressed in endothelial cells (GATA2; Khandekar et al., 2007) 
or in LECs (SOX18, MEF2C, or PROX1; Wigle and Oliver, 
1999; Wick et al., 2007; Francois et al., 2008; unpublished data). 
86% of the FOXC2 ChIP sequences were found to contain at 
least one NFAT consensus sequence using a threshold of 3.4, 
which detects FOXC2-binding sites in 80% of the ChIP 
sequences (Table S1). Further experimental validation of the ran-
domly selected 200-bp fragments from FOXC2 ChIP peak 
regions (Fig. S4 D) by EMSA revealed that NFATc1 strongly 
interacted with fragments 3, 4, 7, and 8 but not with fragments 1, 2, 
5, 6, and 9. This observation was in agreement with the presence 
of NFAT consensus sites in the fragments 3, 4, 7, and 8 (Fig. 10 B; 
unpublished data). We next tested the fragments in luciferase re-
porter analysis and found that fragment 8 showed synergistic ac-
tivation in the presence of both NFATc1 and FOXC2 compared 
with weak activation when either transcription factor was present 
alone (Fig. 10 C). Interestingly, the NFATc1-dependent acti-
vation of the reporter fragment 3 was partially repressed by FOXC2, 
whereas activity of reporter fragments 1 and 2 was not modified. 
The absence of response to FOXC2 of the reporters 1 and 2 could 
be a result of the fact that some 200-bp ChIP fragments may lack 
control elements needed for the efficient transcriptional regula-
tion in our reporter system, or, alternatively, only the fragments 
that harbor both NFAT- and FOXC2-binding sites are capable of 
directing transcription. To investigate the mechanisms of tran-
scriptional regulation by FOXC2 and NFATc1 in more detail, we 
performed site-directed mutagenesis of the reporter fragment 8, 
which contained three potential FOXC2-binding sites and one 
NFAT-binding site. Inactivation of FOXC2 site 1 proximal to the 
NFAT site significantly reduced the response to NFATc1, whereas 
mutations of more distal FOXC2 sites 2 and 3 had less pro-
nounced effects (Fig. 10 D). These results suggest that FOXC2 
binding is required for further reporter activation by NFATc1.
In summary, we have identified FOXC2-binding sites in 
primary LECs using an unbiased genome-wide location mapping 
approach and showed that a subset of these regions is enriched 
ChIP-chip results. 33P-labeled 200-bp DNA probes from selected ChIP regions (Fig. S4 D) were incubated with nuclear extracts from LECs transduced with 
FOXC2-expressing (AdFOXC2) or control adenovirus (AdLacZ), and the resulting DNA–protein complexes were analyzed by EMSA. GAPDH probe was 
used as a negative control. (C) Distribution of FOXC2-binding sites in the human genome. ChIP regions were mapped to their nearest RefSeq genes using 
CEAS (Ji et al., 2006). Proximal promoters and immediate downstream regions were defined as ≤1 kb upstream from the transcription start site or ≤1 kb 
downstream from the 3 end of a gene, respectively. Distal intergenic refers to all locations outside the boundaries of a gene and the 1 kb flanking the gene 
on either end. UTR, untranslated region. (D) FOXC2-binding regions are conserved among higher eukaryotes. ChIP regions were uniformly expanded to 
3 kb, aligned at the center, and the mean phastCons conservation score (Siepel et al., 2005) was retrieved from the University of California Santa Cruz 
genome resource (http://genome.ucsc.edu) for each aligned position. The mean phastCons score was plotted against the distance from ChIP region cen-
ter (1.5 kb upstream and downstream). (E) Comparison of a novel FOXC2-binding motif identified by MEME analysis of ChIP-chip data with the Freac-3 
(FOXC1) motif from the TRANSFAC database. The region of similarity is boxed. Chr, chromosome.
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scription. Collectively, these data provide a molecular basis for 
the observed in vivo cooperation between the NFATc1 and 
FOXC2 signaling in the developing lymphatic vasculature.
in NFAT-binding sites. In addition, we demonstrated that NFATc1 
and FOXC2 interact with ChIP-derived DNA and that these two 
transcription factors can cooperate in the regulation of tran-
Figure 10. Cooperation of FOXC2 and NFATc1 signaling. (A) Enrichment of FOXC2- and NFATc1-binding sites in ChIP sequences. Red points indicate 
the number of sites observed in the original ChIP sequences, showing that both FOXC2 (de novo–discovered matrix)- and NFAT (M00302 and M00935)-
binding sites are highly enriched compared with the randomized sequences. PAX6 (M0097), CEBPB (M00109), ATF3 (M00513), BCL6 (M01183), and 
MYCMAX (M00322) are shown as examples of nonenriched sites. (B) NFATc1 interacts with a subset of FOXC2 ChIP regions. 33P-labeled DNA probes of 
200 bp from selected ChIP peak regions (Fig. S4 D) were incubated with recombinant NFATc1 protein together with anti-NFATc1 or control antibodies, 
and the resulting DNA–protein complexes were analyzed by EMSA. (C) Coregulation by FOXC2 and NFATc1. Selected 200-bp fragments of ChIP peak 
regions (Fig. S4 D) were subcloned into a pTA-luc luciferase reporter, and the luciferase activity was analyzed after cotransfection with either empty expres-
sion vector, expression vectors for FOXC2 or NFATc1, or both FOXC2 and NFATc1. (D) Mutations in FOXC2-binding sites reduce coactivation by NFATc1. 
Luciferase activity was analyzed after cotransfection of wild-type (WT) or mutated fragment 8/pTA-luc luciferase reporters with either empty expression 
vector, expression vectors for FOXC2 or NFATc1, or cotransfection with both FOXC2 and NFATc1. Data are presented as the mean ± SD.
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Discussion
Blood vessel maturation, which starts with establishment of the 
venous-arterial identity and continues with the remodeling by 
sprouting, splitting, fusion, and pruning of preexisting vessels, 
recruitment of mural cells, and the deposition of a basement 
membrane and a perivascular ECM, has been extensively studied 
over recent years (Risau, 1997; Jain, 2003; Sato, 2003; Davis and 
Senger, 2005; Chantrain et al., 2006; Lamont and Childs, 2006). 
However, much less is known about the corresponding develop-
mental process in the lymphatic vasculature. In this study, we de-
scribe the morphological and molecular changes that lead to the 
formation of the collecting lymphatic vessels during develop-
ment. We conclude that the transcription factors FOXC2 and 
NFATc1 control this process and are responsible for establishing 
a collecting lymphatic vessel identity by binding to proximal sites 
on the DNA and regulating expression of downstream genes.
Discovery of lymphatic endothelial specific markers and 
molecular regulators, such as Prox1, VEGF-C–VEGFR-3, Foxc2, 
and LYVE-1, has significantly advanced our understanding of 
lymphatic vascular biology (Oliver, 2004; Makinen et al., 2007). 
In this study, we show that the specialization of lymphatic vessels 
into collecting vessels and capillaries is characterized by down-
regulation of lymphatic capillary markers LYVE-1, VEGFR-3, 
and SLC (Makinen et al., 2005; and this study), which is preceded 
by changes in the expression pattern of the transcription factors 
Foxc2 and Prox1. The role of LYVE-1 and SLC down-regulation 
in collecting lymphatic vessel function remains to be investi-
gated. In contrast, down-regulation of VEGFR-3 is likely to be 
important for the establishment of a quiescent phenotype of col-
lecting lymphatic vessels, which act essentially as lymph conduits, 
whereas lymphatic capillaries continue to express high levels of 
VEGFR-3 and serve as primary sites of lymphangiogenic re-
sponse (Wirzenius et al., 2007). Such balance in response to 
VEGF-C signaling would also be important to ensure maximally 
efficient lymph transport. Accumulation of ECM and basement 
membrane components, as well as recruitment of pericytes and 
SMCs, is a relatively late event in the establishment of a collect-
ing vessel identity, which follows the changes in gene expres-
sion in the lymphatic endothelium. Interestingly, VEGFR-3, 
Prox1, and Foxc2 levels remain high in the developing and adult 
intraluminal valves, suggesting that valve LECs are molecularly 
distinct from the nearby cells in the collecting vessel trunk, per-
haps as a result of distinct mechanosensory transduction in these 
two regions and the need for the constant repopulation of endo-
thelial cells in the valves.
Sharp up-regulation of Foxc2 at E15–15.5 is the earliest 
observed event during the formation of collecting vessels. Fur-
thermore, genetic loss of Foxc2 leads to failure in the remodel-
ing and the accompanying down-regulation of Prox1, VEGFR-3, 
LYVE-1, and SLC in maturing lymphatic vessels, which instead 
remain in an immature capillary-like state. Studies of the blood 
vasculature have demonstrated a functional separation of endo-
thelial cells in angiogenic sprouts into stalk cells and tip cells, 
the latter characterized by extensive formation of filopodia, which 
is important for correct vessel guidance and establishment of 
a properly patterned vascular network in response to a VEGF 
gradient (Gerhardt et al., 2003). In this study, we show that in spite 
of excessive VEGFR-3 expression and lymphatic vessel hyper-
plasia, the Foxc2-deficient capillary plexus is paradoxically 
characterized by defective sprouting. Although the exact cause 
remains to be investigated, this is possibly a result of abnormal 
deposition of collagen IV around nascent tip cells, which could 
prevent formation of tip cell filopodia and normal vessel guid-
ance and patterning. An important remaining question concerns 
the signals controlling Foxc2 expression in the developing lym-
phatic vasculature; studies from other cell types show that TGF- 
or BMP2 can induce FOXC2 in vitro (Yang et al., 2000; Mani 
et al., 2007). Future studies of mice with conditional ablation of 
TGF or bone morphogenetic proteins signaling components in 
the lymphatic endothelium should clarify the contribution of these 
pathways to Foxc2 regulation.
In search of similarities between the molecular mecha-
nisms of cardiac and lymphatic valve formation, we found that 
NFATc1, a transcription factor that controls the morphogenesis 
of cardiac valves, is expressed in the developing lymphatic vas-
culature and intraluminal valves. Our data from primary LECs 
show that PROX1, at least in part, controls the LEC-specific 
expression of NFATc1, whereas the lymphangiogenic growth 
factor VEGF-C induces NFATc1 nuclear translocation through 
activation of VEGFR-2. The relative extent of the contribution of 
VEGFR-2–VEGFR-2 homodimeric versus VEGFR-2–VEGFR-3 
heterodimeric complexes to NFATc1 activation remains to be 
determined; however, the inability of VEGFR-3 signaling alone 
to activate NFATc1 nuclear translocation suggests that in the 
lymphatic endothelium VEGFR-2– or VEGFR-2–VEGFR-3–
mediated pathways are more important for the establishment of 
collecting vessel phenotype rather than for the formation of a 
capillary network. In agreement with this hypothesis, VEGFR-2 
is highly expressed in collecting lymphatic vessels and valves 
(Saaristo et al., 2002b; Wirzenius et al., 2007; unpublished 
data) where it promotes lymphatic vessel enlargement, whereas 
VEGFR-3 signaling is responsible for capillary sprouting 
(Wirzenius et al., 2007).
In addition to its role in endocardial cells, NFAT signaling 
in the blood vascular endothelium is important for cell prolifer-
ation, expression of proinflammatory genes, vascular patterning 
during early embryogenesis, and angiogenesis under pathological 
conditions (Schulz and Yutzey, 2004; for review see Crabtree 
and Olson, 2002). Our in vivo data, from Nfatc1-deficient mice 
and after inhibition of NFAT activation by CsA, show that the 
calcineurin/NFAT pathway does not contribute to angiogenesis 
at late stages of embryonic development, nor does it affect LEC 
commitment. Instead, loss of NFAT signaling impairs the matu-
ration and remodeling of the lymphatic vasculature as indicated 
by persistent expression of lymphatic capillary markers, lymphatic 
vessel hyperplasia, reduced formation of lymphatic valves, and 
impaired sprouting. These phenotypes, reminiscent of the ones 
observed in Foxc2/ mice, are strongly enhanced upon loss 
of one Foxc2 allele, suggesting a genetic interaction between 
these two pathways. However, in CsA-treated mice, Foxc2 ex-
pression is high in all LECs, whereas NFATc1 expression is 
normal in Foxc2-deficient mice. These results indicate that 
Foxc2 and NFATc1 are expressed independently of each other 
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et al., 1998; DasGupta and Fuchs, 1999; Gale et al., 2002; Maretto et al., 
2003). For experiments involving only wild-type mice, outbred ICR or NMRI 
mice were used. Embryonic age was determined according to the day of the 
vaginal plug (E0.5). For NFAT inhibition, E12.5–16.5 pregnant mice were 
given 50 mg/kg CsA (EMD) in 10% DMSO in sunflower seed oil (Sigma-
Aldrich) or DMSO in oil only twice a day by oral gavage.
For fluorescent lymphangiography, embryos were injected with 
10 mg/ml FITC-dextran in PBS (2,000-kD molecular mass; Sigma-Aldrich) 
subcutaneously in the hind limbs immediately after dissection, and flank 
collecting lymphatic vessels were visualized by fluorescence microscopy.
Antibodies, staining procedures, and image acquisition
Mesenteries and skins were dissected, fixed in 4% PFA, and whole-mount 
staining was performed as described previously (Saaristo et al., 2002a; 
Tammela et al., 2005). 6-µm deparaffinized tissue sections were subjected 
to heat-induced epitope retrieval (High pH Retrieval Solution; Dako). Cul-
tured cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, 
and blocked with 5% donkey serum. For stainings, we used rat anti–mouse 
Foxc2 (Furumoto et al., 1999), mouse anti–human NFATc1 (clone 7A6; 
Santa Cruz Biotechnology, Inc.; Timmerman et al., 1997), rabbit anti–
human PROX1 (Karkkainen et al., 2004), goat anti–mouse VEGFR-3 (R&D 
Systems), rabbit anti–mouse LYVE-1 (Petrova et al., 2004), rat anti–mouse 
PECAM-1 (BD), rabbit anti–mouse NG2 (Millipore), Cy3-conjugated mouse 
anti–human -SMA (Sigma-Aldrich), rabbit anti–mouse collagen IV (Cosmo 
Bio), and goat anti–mouse SLC (R&D Systems). Alexa Fluor 488, 594, and 
647 fluorochrome-conjugated secondary antibodies (Invitrogen) were used 
for signal detection. The tyramide signal amplification method (Tyramide 
Signal Amplification Indirect; PerkinElmer) was used for the detection of 
VEGFR-3 after in situ hybridization.
Samples were mounted with DAPI-containing Vectashield (Vector 
Laboratories) and analyzed at room temperature with a confocal micro-
scope (LSM 510 Meta; Carl Zeiss, Inc.) using LSM AIM software or an epi-
fluorescent microscope (Axioplan 2; Carl Zeiss, Inc.) equipped with a 
charge-coupled device camera (AxioCam HRc; Carl Zeiss, Inc.) using 
Axiovision software (version 4.6; Carl Zeiss, Inc.). Objectives used were 10× 
Plan-Apochromat NA 0.45, 10× Fluar NA 0.5, 10× Plan-Neofluar NA 
0.3, 20× Plan-Neofluar NA 0.5, 40× Plan-Apochromat NA 1.3, 40× long-
distance C-Apochromat NA 1.1, and 40× Plan-Neofluar NA 0.75 (Carl 
Zeiss, Inc.). Three-dimensional projections of whole-mount images were 
digitally reconstructed from confocal z stacks using LSM AIM software and 
processed using Photoshop (CS; Adobe). Images are representative pic-
tures from three to five embryos/stage or phenotype.
In situ hybridization
Frozen sections or whole-mount mesenteries from E17.5 embryos were 
used and processed as described previously (Wilkinson, 1998). Sections 
were hybridized with complementary RNA anti-sense or sense probes for 
Angpt2 (nucleotides 45–738 from GenBank under accession no. NM_
007426), NFATc1 (nucleotides 1,012–1,519 from GenBank under acces-
sion no. NM_016791), or Prox1 (nucleotides 276–1,208 from GenBank 
under accession no. NM_002763).
Cell culture, transfections, transductions, and luciferase reporter assays
Human iLECs were isolated as described previously (Haraldsen et al., 
1995; Jahnsen et al., 1997) and cultured in endothelial cell growth 
medium (PromoCell). Lymphatic endothelial identity was confirmed with 
PROX1 staining. For growth factor treatments, iLECs were starved for 6 h, 
treated with 200 ng/ml CsA (EMD) in DMSO or only DMSO for 2 h in star-
vation medium, and stimulated with 200 ng/ml NC VEGF-C (Karpanen 
et al., 2006), 500 ng/ml NC VEGF-C(C156S) (Heckman et al., 2008), 
and 500 ng/ml VEGF-E NZ7 (Gerhardt et al., 2003) for 20 min. For 
siRNA experiments, iLECs were transfected with 10–40 nM siRNA using 
Lipofectamine 2000 (Invitrogen) and the following siRNAs: PROX1, 
5-CUAUGAGCCAGUUUGAUAUUU-3 (Thermo Fisher Scientific); FOXC2, 
5-AGGTGGTGATCAAGAGCGAUU-3; or siRNA Allstars Control (Invit-
rogen). Cells were lysed 48–96 h after transfection. For adenoviral ex-
periments, iLECs were transduced with 20–50 plaque-forming unit/cell 
recombinant adenoviruses encoding human PROX1 (Petrova et al., 2002), 
FOXC2 (Petrova et al., 2004), or LacZ (Laitinen et al., 1998) in serum-free 
medium for 1 h and lysed 48 h after transfection. For luciferase reporter 
assays, 183–199-bp sequences from selected ChIP peak regions were sub-
cloned into pTA luciferase reporter vector. 293T cells were cotransfected 
with reporter constructs and constitutively active NFATc1 (plasmid 11102; 
Addgene; Monticelli and Rao, 2002), FOXC2 (Petrova et al., 2004), and 
empty vectors using jetPEI transfection reagent (Polyplus-Transfection). 
and suggest that they act by coregulating transcription of 
downstream genes.
To gain mechanistic understanding of the role of FOXC2 
in LECs, we performed a genome-wide analysis of FOXC2-
binding sites. Previous studies suggested several FOXC2 target 
genes in blood vascular endothelium based on computational 
analysis of proximal promoters (Hayashi and Kume, 2008a,b; 
Hayashi et al., 2008). In this report, we have studied the asso-
ciation of FOXC2 across the entire genome, and we show that the 
vast majority of FOXC2-binding sites are located in the inter-
genic and intronic regions, arguing that FOXC2 acts primarily 
via distal enhancers as previously observed for estrogen-related 
receptor  and FOXa1 (Carroll et al., 2005; Lupien et al., 2008). 
The analysis of FOXC2 ChIP sequences demonstrated that 
NFAT-binding sites are strongly enriched in the proximity of 
FOXC2-binding sites. Based on this observation, we experi-
mentally confirmed that NFATc1 binds to FOXC2 ChIP-derived 
fragments containing NFAT consensus and that it can direct 
transcription in reporter assays, thus providing the molecular 
basis for the NFAT and FOXC2 cooperation in vivo. The out-
standing remaining question concerns the identification of 
FOXC2/NFATc1 effector genes or pathways responsible for 
establishment of the lymphatic collecting vessel phenotype. 
Future studies, including the combination of ChIP-chip data 
with chromosome capture analysis, gene expression profiling of 
Foxc2-deficient LECs, and large-scale screening studies in 
small vertebrate models of lymphatic vascular development, 
such as zebrafish or Xenopus laevis, will be invaluable to 
answer these questions.
In conclusion, our data provide a new understanding of 
the developmental regulation of lymphatic vessels and the role 
of Foxc2 in establishing a collecting vessel identity and intro-
duce a novel role for the transcription factor NFATc1 in lym-
phatic development. Based on our findings, we propose a model 
for the role of Foxc2 and NFATc1 in establishing the identity of 
collecting lymphatic vessels. During normal lymphatic devel-
opment, maturing lymphatic vessels up-regulate Foxc2, and 
VEGF-C–VEGFR-2/3 signaling activates NFATc1, which together 
start a genetic program for formation of collecting vessels. 
Deficiency in either Foxc2 or active NFATc1 in the lymphatic 
endothelium affects the expression of target genes, shutting down 
the program for establishment of a collecting vessel identity and 
leading to a persistent capillary-like phenotype. As damage to 
collecting vessels is a leading cause of secondary lymphedema, 
which frequently develops after cancer surgery–associated 
lymph node dissection, our data suggest that therapeutic deliv-
ery of FOXC2 and constitutively active NFATc1 could repre-
sent a strategy for treatment of secondary lymphedema through 
enhanced regeneration of collecting lymphatic vessels.
Materials and methods
Animal models and in vivo analyses
Animal experiments were approved by the National Animal Ethics Commit-
tee and were performed in accordance with institutional guidelines. Foxc2/ 
mice were bred on the ICR background and genotyped as described previ-
ously (Iida et al., 1997; Petrova et al., 2004). NFATc1/, Angpt2+/lacZ, 
TOP-Gal mice, and BAT-Gal mice have been described previously (Ranger 
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0.04 mg/ml poly-deoxy-inosinic-deoxy-cytidylic acid, 0.4 mg/ml BSA, 
-33P–labeled DNA probe, and cell lysates or 0.8 µg recombinant human 
NFATc1 protein (SignalChem). For supershifts, 1 µg rat anti–mouse Foxc2, 
mouse anti–human NFATc1, or control antibodies from the same species 
were added to the reaction mixtures. After incubation for 30 min at room 
temperature, probes were loaded on 5% criterion Tris-Borate-EDTA poly-
acrylamide gel (Bio-Rad Laboratories). Electrophoresis was performed for 
1–2 h at 10–20 mA/100–150 V. The gels were dried and visualized by 
autoradiography or using a phosphorimager.
Immunoprecipitation and Western and Northern blotting
For analysis of protein interaction, 293T cells were cotransfected with HA-
NFATc1 and FOXC2 expression vectors using Lipofectamine 2000 (Invitro-
gen). 48 h after transfection, cells were lysed with buffer containing 20 mM 
Tris, pH 7.8, 500 nM NaCl, 1% NP-40, and complete protease inhibitor 
mixture (Roche). The lysates were sonicated, spinned down, precleared 
with protein G–Sepharose beads (GE Healthcare), incubated overnight 
with anti-HA antibodies (Abcam) or control nonimmune rabbit IgG (Sigma-
Aldrich), and incubated with protein G–Sepharose beads. The precipitates 
were washed with lysis buffer, resuspended in Laemmli sample buffer, and 
heated at 95°C for 10 min.
For Western blotting, samples were resolved by SDS-PAGE, trans-
ferred onto Immobilon-P membrane (Millipore), and blotted with mono-
clonal antibodies against Foxc2 (Furumoto et al., 1999), NFATc1 (clone 7A6; 
Santa Cruz Biotechnology, Inc.), PROX1 (R&D Systems), phospho–VEGFR-2 
(Tyr1175; Cell Signaling Technology), phospho-ERK1/2 (Cell Signaling 
Technology), and GAPDH (Europa Bioproducts). Western blots were devel-
oped using the ECL method (SuperSignal West Femto Maximum Sensitivity 
Substrate; Thermo Fisher Scientific).
For Northern analysis, 10 µg total RNA was separated in a 1% 
agarose gel, and blots were hybridized in ULTRAhyb solution (Applied Bio-
systems) with a 32P-labeled fragment of human NFATc1 (nucleotides 
2,577–2,825 from GenBank under accession no. NM_006162).
Quantification and statistical analysis
Mesenteric valves were identified as areas of strongly positive Prox1 stain-
ing and counted from duodenum to ileum (n = 4 for each genotype and 
treatment; E17.5). The mean vessel widths of dermal capillaries (n = 4) 
were calculated using Matlab (Mathworks) by dividing vessel area 
(determined by thresholding) by length (determined by a skeletonization 
algorithm by Nicholas R. Howe, Smith College, Northampton, MA). For 
colocalization of Foxc2 and NFATc1, LECs were counted from nine differ-
ent lymphatic vessels from paraffin sections of three wild-type E17.5 em-
bryos. For analysis of nuclear NFATc1 intensity in LECs, RGB images were 
analyzed with the CellCounter program (developed by V. Rantanen, Mo-
lecular Imaging Unit, University of Helsinki). Values were counted from nu-
clear NFATc1 staining and expressed as mean percentual intensity of 
maximum pixel intensity. A two-tailed, unpaired Student’s t test was per-
formed to determine statistical significance by the probability of difference 
between the means.
Online supplemental material
Fig. S1 shows LEC clusters and filopodia in the developing mouse mes-
entery at E14.5 and heterogeneous expression of LYVE-1 in embryonic 
mesentery and skin during development. Fig. S2 shows analysis of NFATc1 
expression by in situ hybridization, colocalization with Foxc2, inhibition 
of NFATc1 nuclear translocation, and Foxc2 expression in CsA-treated 
mice. Fig. S3 shows activation of ERK1/2 phosphorylation by wild-type 
and mutant growth factors, equal NFATc1 mRNA levels in iLECs after 
growth factor stimulation, and an increase in overall NFATc1 expression 
upon PROX1 overexpression, coimmunoprecipitation of FOXC2, and 
NFATc1. Fig. S4 shows Western blots of FOXC2 ChIP experiments, bind-
ing of FOXC2 to ChIP targets in EMSA, which is abolished by mutations 
in FOXC2-binding sites, and a table with ChIP region fragments used in 
EMSAs and luciferase reporter assays. The supplemental data contains 
the CEAS annotation results of all FOXC2 ChIP sequences, whereas Table 
S1 shows FOXC2 ChIP regions that also were found to contain NFAT-
binding sites. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200901104/DC1.
We thank Dr. Elaine Fuchs and Dr. Nicole Stokes (Howard Hughes Medical 
Institute, The Rockefeller University, New York, NY) for E15.5 NFATc1/ 
embryos, Drs. Gerald Crabtree and Wen Qi Ho (Stanford University School of 
Medicine, Stanford, CA) for E12.5 NFATc1/ embryos, Dr. Stefano Piccolo 
(University of Padua, Padua, Italy) for BAT-Gal mice, Dr. Michael Jeltsch (Uni-
versity of Helsinki) for VEGF-C and VEGF-E proteins, Dr. Caroline Heckman 
Renilla luciferase pCMV-RL (provided by C. Heckman, University of Helsinki, 
Helsinki, Finland) was used for normalization of transfection efficiency. 
48 h after transfection, cells were lysed and analyzed using Dual-Luciferase 
kit (Promega). Mutations in FOXC2-binding sites in fragment 8 were in-
troduced using site-directed mutagenesis with the following primers: NFAT 
mutant, 5-CAAAAACACACTCCAACCTTTCC-3 and 5-GATGTAGGTC-
TAAGGGCGAATTC-3; FOXC2 mutant 1, 5-GACAGAAACCTATTATTG-
GAAACAATT-3 and 5-CGTTCAGGGTAGGAGAAGGGAAG-3; FOXC2 
mutant 2, 5-GACAGGATTCATATATTTCATCC-3 and 5-CATAGACGTG-
TATGAAATAATTGTT-3; and FOXC2 mutant 3, 5-GACATGTCAAAATAG-
GAAGCCCA-3 and 5-CTTATTTCCTGGATGAAATATATGAATCCTGT-3. 
The presence of mutations was verified by sequencing. Experiments were 
done in triplicate and repeated at least three times. Values are expressed 
as fold increase compared with empty control ± SD.
ChIP-chip analysis
ChIP-chip was performed essentially as described by O’Geen et al., (2006) 
with the following modifications: iLECs were cross-linked with formaldehyde 
in complete endothelial cell basal medium MV (PromoCell), and IP dilution 
buffer was substituted with 3% BSA containing complete inhibitor tablets 
(Roche). DNA was sheared using a sonicator (Soniprep 150; MSE) and 
immunoprecipitated using rat anti–mouse Foxc2 antibody (Furumoto et al., 
1999) complexed with protein G–Sepharose (GE Healthcare). Decross-
linked ChIP DNA was amplified using GenomePlex Complete Whole 
Genome Amplification kit (Sigma-Aldrich) using the buffer supplemented 
with deoxynucleotide-triphosphate + deoxy-UTP mixture. DNA was 
fragmented using uracil DNA glycosylase and apurinic/apyrimidinic endo-
nuclease. Terminal labeling, hybridization, and array processing were per-
formed as recommended by the array manufacturer (Affymetrix). Three 
biologically independent ChIP replicates and two control IgG replicates were 
hybridized to GeneChip Human Tiling 2.0R Array Sets (Affymetrix). Data 
analysis was performed using MAT software (Johnson et al., 2006) at 0.1% 
FDR cutoff (intensity analysis parameters: BandWidth = 300, MaxGap = 
300, MinProbe = 10). A total of 2,359 FOXC2-enriched regions were identi-
fied of which nine mitochondrial sequences were discarded from further anal-
ysis. Enriched regions were visualized using Integrated Genome Browser 
software (Affymetrix). Initial analyses of evolutionary conservation, nearby 
genes, and enriched transcription factor–binding motifs were performed using 
cis-regulatory element annotation system (CEAS) software (Ji et al., 2006).
Bioinformatics analyses of ChIP-chip data
400-bp-long fragments from the center of each ChIP sequence were ex-
tracted and ranked according to the p-value. The fragments were split in 
10 bins of 235 sequences each, with bin 1 containing the sequences with 
the lowest p-values and bin 10 containing the sequences with the highest 
p-values. De novo motif discovery was performed in each bin separately 
using the program MEME (multiple EM for motif elicitation; Bailey and 
Elkan, 1994) in the mode of one occurrence per sequence and a motif width 
ranging from 7 to 15. MEME results were confirmed by the Gibbs sampler 
(Thompson et al., 2003) with default options.
The de novo–discovered FOXC2-binding site and all vertebrate tran-
scription factor–binding sites stored as TRANSFAC matrices (Matys et al., 
2003) were turned into calibrated profiles using the pftools program 
(Bucher et al., 1996; Roulet et al., 2002). To select a stringency threshold 
defining binding site predictions of high quality, several score thresholds were 
applied to detect potential FOXC2-binding sites in the 2,350 ChIP se-
quences, and the threshold of 3.4 was selected, as it predicted a FOXC2-
binding site in 80% of the sequences. This same threshold was then used to 
predict the positions of other transcription factor–binding sites such as NFAT. 
The NFAT matrix 1 has been derived from 26 experimentally identified 
endogenous NFAT-binding sites (Kel et al., 1999), and the NFAT matrix 2 has 
been derived from a selection of the same sites used for matrix 1 plus eight 
additional TRANSCompel sites. The same 3.4 cutoff was used to compute 
random matches in 1,000 random sets, which were composed of randomly 
shuffled ChIP sequences with a window of 20 nucleotides. The enrichment, 
or fold change, was computed as the ratio of the number of ChIP matches 
and the mean number of random matches. The 95% confidence interval for 
the enrichment ratios was estimated assuming that the sampling distribution 
is approximately Gaussian for the log ratio and Poisson for the counts. 
For the analysis of putative PROX1-binding sites, the matrix for Drosophila 
melanogaster prospero was used (Choksi et al., 2006).
EMSA
25 µl EMSA reaction mixtures contained 10 mM Hepes, pH 8.0, 3 mM 
Tris–HCl, pH 8.0, 50 mM KCl, 2 mM MgCl2, 10% glycerol, 1 mM dithiotreitol, 
JCB • VOLUME 185 • NUMBER 3 • 2009 456
(University of Helsinki) for the pCMV-RL luciferase plasmid, and Dr. Ernest Mueller 
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